+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Osteosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 316 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589923
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Drugs In Development, 2022, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 46, 20, 1, 38 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 7 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionReport CoverageOsteosarcoma - Overview
Osteosarcoma - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Osteosarcoma - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Osteosarcoma - Companies Involved in Therapeutics DevelopmentOsteosarcoma - Drug ProfilesOsteosarcoma - Dormant ProjectsOsteosarcoma - Discontinued ProductsOsteosarcoma - Product Development Milestones
Featured News & Press Releases
  • Apr 11, 2022: Adcendo presents data on uPARAP targeting ADCs in osteosarcoma PDX models at the 2022 AACR Annual Meeting
  • Jan 27, 2022: OS Therapies announces nationwide open enrollment of remaining 36 to 42 patients in phase IIb trial of OST-HER2 (Listeria monocytogenes) in recurred, resected osteosarcoma
  • Nov 03, 2021: OS Therapies receives Rare Pediatric Disease Designation (RDD) in osteosarcoma for OST-HER2 (Listeria monocytogenes)
  • Oct 25, 2021: OS Therapies doses first subject in Phase IIb osteosarcoma therapy trial
  • Jun 23, 2021: Children's Cancer Research Fund supports AOST-2121 PhIIb clinical trial in recurred, resected osteosarcoma
  • Apr 26, 2021: Advaxis announces achievement of second milestone under ADXS-HER2 licensing agreement with OS Therapies
  • Mar 09, 2021: Allarity Therapeutics announces positive data from preclinical study of dovitinib in osteosarcoma
  • Feb 05, 2021: WPD Pharmaceuticals’ licensor announces 100% survival achieved in osteosarcoma lung metastases animal model of annamycin drug
  • Feb 02, 2021: Moleculin announces 100% survival achieved in osteosarcoma lung metastases animal model
  • Jan 26, 2021: OS Therapies receives trial approval from Children's Oncology Group for AOST2121 / OST31-164-01 an open-label Phase 2 study of maintenance therapy with OST31-164 after resection of recurrent osteosarcoma
  • Jan 19, 2021: Advaxis announces receipt of funding milestone payment under ADXS-HER2 licensing agreement with OS Therapies
  • Nov 23, 2020: Hillstream BioPharma’s HSB-888 receives rare pediatric disease designation and orphan drug designation for osteosarcoma
  • Nov 19, 2020: Eisai to present new investigational data on LENVIMA (lenvatinib) in thyroid cancer and osteosarcoma at ESMO Asia 2020
  • Sep 24, 2020: Innova Therapeutics receives Rare Pediatric Disease Designation from the Food and Drug Administration (FDA) for IVT-8086 for the treatment of Osteosarcoma
  • Sep 11, 2020: Eisai to present abstracts on lenvatinib mesylate at ESMO Virtual Congress 2020
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Osteosarcoma, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Osteosarcoma - Pipeline by Aadi Bioscience Inc, 2022
  • Osteosarcoma - Pipeline by Actuate Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by ADCendo ApS, 2022
  • Osteosarcoma - Pipeline by Advanced BioDesign, 2022
  • Osteosarcoma - Pipeline by Advaxis Inc, 2022
  • Osteosarcoma - Pipeline by Advenchen Laboratories LLC, 2022
  • Osteosarcoma - Pipeline by Allarity Therapeutics A/S, 2022
  • Osteosarcoma - Pipeline by Anagenics Ltd, 2022
  • Osteosarcoma - Pipeline by AntiCancer Inc, 2022
  • Osteosarcoma - Pipeline by APEIRON Biologics AG, 2022
  • Osteosarcoma - Pipeline by API Co Ltd, 2022
  • Osteosarcoma - Pipeline by Astex Therapeutics Ltd, 2022
  • Osteosarcoma - Pipeline by AstraZeneca Plc, 2022
  • Osteosarcoma - Pipeline by Atlanthera, 2022
  • Osteosarcoma - Pipeline by Aurora BioPharma Inc, 2022
  • Osteosarcoma - Pipeline by Autolus Therapeutics Plc, 2022
  • Osteosarcoma - Pipeline by Bayer AG, 2022
  • Osteosarcoma - Pipeline by Bicycle Therapeutics Plc, 2022
  • Osteosarcoma - Pipeline by BioAtla Inc, 2022
  • Osteosarcoma - Pipeline by BioEclipse Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by BioMarck Pharmaceuticals Ltd, 2022
  • Osteosarcoma - Pipeline by BioMed Valley Discoveries Inc, 2022
  • Osteosarcoma - Pipeline by Boehringer Ingelheim International GmbH, 2022
  • Osteosarcoma - Pipeline by BrightPath Biotherapeutics Co Ltd, 2022
  • Osteosarcoma - Pipeline by Bristol-Myers Squibb Co, 2022
  • Osteosarcoma - Pipeline by CanBas Co Ltd, 2022
  • Osteosarcoma - Pipeline by Cellectar Biosciences Inc, 2022
  • Osteosarcoma - Pipeline by Cellestia Biotech AG, 2022
  • Osteosarcoma - Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd, 2022
  • Osteosarcoma - Pipeline by CorMedix Inc, 2022
  • Osteosarcoma - Pipeline by CSPC Pharmaceutical Group Ltd, 2022
  • Osteosarcoma - Pipeline by Curamir Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by Dnatwo Inc, 2022
  • Osteosarcoma - Pipeline by Eisai Co Ltd, 2022
  • Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, 2022
  • Osteosarcoma - Pipeline by ENB Therapeutics LLC, 2022
  • Osteosarcoma - Pipeline by Epeius Biotechnologies Corp, 2022
  • Osteosarcoma - Pipeline by Exelixis Inc, 2022
  • Osteosarcoma - Pipeline by GlaxoSmithKline Plc, 2022
  • Osteosarcoma - Pipeline by GlycoMimetics Inc, 2022
  • Osteosarcoma - Pipeline by Guangzhou Sinogen Pharmaceutical Co Ltd, 2022
  • Osteosarcoma - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
  • Osteosarcoma - Pipeline by Hillstream BioPharma Inc, 2022
  • Osteosarcoma - Pipeline by HRYZ (ShenZhen) Biotech Co, 2022
  • Osteosarcoma - Pipeline by Hutchison MediPharma Ltd, 2022
  • Osteosarcoma - Pipeline by Idera Pharmaceuticals Inc, 2022
  • Osteosarcoma - Pipeline by ImmunityBio Inc, 2022
  • Osteosarcoma - Pipeline by Incuron, 2022
  • Osteosarcoma - Pipeline by Innova Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by Intezyne Inc, 2022
  • Osteosarcoma - Pipeline by Iovance Biotherapeutics Inc, 2022
  • Osteosarcoma - Pipeline by Ipsen SA, 2022
  • Osteosarcoma - Pipeline by Isofol Medical AB, 2022
  • Osteosarcoma - Pipeline by Iterion Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by ITM Isotopen Technologien Munchen AG, 2022
  • Osteosarcoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
  • Osteosarcoma - Pipeline by Joint Biosciences Ltd, 2022
  • Osteosarcoma - Pipeline by K-Group Beta Inc, 2022
  • Osteosarcoma - Pipeline by Komipharm International Co Ltd, 2022
  • Osteosarcoma - Pipeline by Kyowa Kirin Co Ltd, 2022
  • Osteosarcoma - Pipeline by MacroGenics Inc, 2022
  • Osteosarcoma - Pipeline by Mana Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by MD Biosciences GmbH, 2022
  • Osteosarcoma - Pipeline by MediaPharma SRL, 2022
  • Osteosarcoma - Pipeline by MedPacto Inc, 2022
  • Osteosarcoma - Pipeline by Merck & Co Inc, 2022
  • Osteosarcoma - Pipeline by Merck KGaA, 2022
  • Osteosarcoma - Pipeline by MetCure Therapeutics LLC, 2022
  • Osteosarcoma - Pipeline by Moleculin Biotech Inc, 2022
  • Osteosarcoma - Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2022
  • Osteosarcoma - Pipeline by Nkarta Inc, 2022
  • Osteosarcoma - Pipeline by Novartis AG, 2022
  • Osteosarcoma - Pipeline by Oncolys BioPharma Inc, 2022
  • Osteosarcoma - Pipeline by Oncotelic Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, 2022
  • Osteosarcoma - Pipeline by Orgenesis Inc, 2022
  • Osteosarcoma - Pipeline by OS Therapies LLC, 2022
  • Osteosarcoma - Pipeline by Peel Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by Pfizer Inc, 2022
  • Osteosarcoma - Pipeline by Pharma Mar SA, 2022
  • Osteosarcoma - Pipeline by Pimera Inc, 2022
  • Osteosarcoma - Pipeline by Provectus Biopharmaceuticals Inc, 2022
  • Osteosarcoma - Pipeline by QSAM Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by Radiopharm Theranostics Ltd, 2022
  • Osteosarcoma - Pipeline by Reven Holdings Inc, 2022
  • Osteosarcoma - Pipeline by Scancell Holdings Plc, 2022
  • Osteosarcoma - Pipeline by Secura Bio Inc, 2022
  • Osteosarcoma - Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2022
  • Osteosarcoma - Pipeline by Shionogi & Co Ltd, 2022
  • Osteosarcoma - Pipeline by Singh Biotechnology LLC, 2022
  • Osteosarcoma - Pipeline by Sorrento Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by Taiho Pharmaceutical Co Ltd, 2022
  • Osteosarcoma - Pipeline by Taithera Inc, 2022
  • Osteosarcoma - Pipeline by Transcode Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by Umoja BioPharma Inc, 2022
  • Osteosarcoma - Pipeline by United Therapeutics Corp, 2022
  • Osteosarcoma - Pipeline by Vaccinex Inc, 2022
  • Osteosarcoma - Pipeline by Veana Therapeutics LLC, 2022
  • Osteosarcoma - Pipeline by Y-mAbs Therapeutics Inc, 2022
  • Osteosarcoma - Pipeline by Zentalis Pharmaceuticals Inc, 2022
  • Osteosarcoma - Dormant Projects, 2022
  • Osteosarcoma - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Osteosarcoma, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aadi Bioscience Inc
  • Actuate Therapeutics Inc
  • ADCendo ApS
  • Advanced BioDesign
  • Advaxis Inc
  • Advenchen Laboratories LLC
  • Allarity Therapeutics A/S
  • Anagenics Ltd
  • AntiCancer Inc
  • APEIRON Biologics AG
  • API Co Ltd
  • Astex Therapeutics Ltd
  • AstraZeneca Plc
  • Atlanthera
  • Aurora BioPharma Inc
  • Autolus Therapeutics Plc
  • Bayer AG
  • Bicycle Therapeutics Plc
  • BioAtla Inc
  • BioEclipse Therapeutics Inc
  • BioMarck Pharmaceuticals Ltd
  • BioMed Valley Discoveries Inc
  • Boehringer Ingelheim International GmbH
  • BrightPath Biotherapeutics Co Ltd
  • Bristol-Myers Squibb Co
  • CanBas Co Ltd
  • Cellectar Biosciences Inc
  • Cellestia Biotech AG
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • CorMedix Inc
  • CSPC Pharmaceutical Group Ltd
  • Curamir Therapeutics Inc
  • Dnatwo Inc
  • Eisai Co Ltd
  • Eleison Pharmaceuticals LLC
  • ENB Therapeutics LLC
  • Epeius Biotechnologies Corp
  • Exelixis Inc
  • GlaxoSmithKline Plc
  • GlycoMimetics Inc
  • Guangzhou Sinogen Pharmaceutical Co Ltd
  • Hebei Senlang Biotechnology Co Ltd
  • Hillstream BioPharma Inc
  • HRYZ (ShenZhen) Biotech Co
  • Hutchison MediPharma Ltd
  • Idera Pharmaceuticals Inc
  • ImmunityBio Inc
  • Incuron
  • Innova Therapeutics Inc
  • Intezyne Inc
  • Iovance Biotherapeutics Inc
  • Ipsen SA
  • Isofol Medical AB
  • Iterion Therapeutics Inc
  • ITM Isotopen Technologien Munchen AG
  • Jiangsu Hengrui Medicine Co Ltd
  • Joint Biosciences Ltd
  • K-Group Beta Inc
  • Komipharm International Co Ltd
  • Kyowa Kirin Co Ltd
  • MacroGenics Inc
  • Mana Therapeutics Inc
  • MD Biosciences GmbH
  • MediaPharma SRL
  • MedPacto Inc
  • Merck & Co Inc
  • Merck KGaA
  • MetCure Therapeutics LLC
  • Moleculin Biotech Inc
  • Nanjing Aimeifei Biomedical Technology Co Ltd
  • Nkarta Inc
  • Novartis AG
  • Oncolys BioPharma Inc
  • Oncotelic Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Orgenesis Inc
  • OS Therapies LLC
  • Peel Therapeutics Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Pimera Inc
  • Provectus Biopharmaceuticals Inc
  • QSAM Therapeutics Inc
  • Radiopharm Theranostics Ltd
  • Reven Holdings Inc
  • Scancell Holdings Plc
  • Secura Bio Inc
  • Shanghai De Novo Pharmatech Co Ltd
  • Shionogi & Co Ltd
  • Singh Biotechnology LLC
  • Sorrento Therapeutics Inc
  • Taiho Pharmaceutical Co Ltd
  • Taithera Inc
  • Transcode Therapeutics Inc
  • Umoja BioPharma Inc
  • United Therapeutics Corp
  • Vaccinex Inc
  • Veana Therapeutics LLC
  • Y-mAbs Therapeutics Inc
  • Zentalis Pharmaceuticals Inc